

# John Mickelson, Ph.D.

## VIKSINNS HARRIS & PADYS PLLP

7900 International Drive, Suite 670

Minneapolis, MN 55425

952.876.4089 (phone)

952.876.4098 (fax)

[jmickelson@vhpglobalip.com](mailto:jmickelson@vhpglobalip.com)

**Practice Areas:** Pharmaceutical-Chemical patent prosecution

### Education

The Upjohn Company, Kalamazoo, MI, Postdoctoral Research Fellow

University of Minnesota, Minneapolis, Ph.D., Organic Chemistry

University of Minnesota, Duluth, B.S., Chemistry (*Magna Cum Laude*)

### Bar Admissions

United States Patent and Trademark Office, December 2008

### Professional Experience

Viksnins Harris & Padys PLLP, Bloomington, Minnesota (September 2007 to present)

Patent Agent; Prepare and prosecute United States and international patent applications for pharmaceutical, chemical and polymer inventions.

Pfizer Global Research and Development, Ann Arbor, Michigan (2003 to 2007)

Senior Principal Research Scientist; Co-chaired drug discovery inflammation project teams and led medicinal chemistry efforts investigating novel mechanisms for the potential treatment of rheumatoid arthritis and the signs and symptoms of arthritis.

Pfizer Global Research and Development (formerly Pharmacia) Kalamazoo, Michigan (2001 to 2003)

Principal Research Scientist; Led medicinal chemistry efforts investigating  $\beta$ -secretase inhibitors for the potential treatment of Alzheimer's disease and CRF inhibitors for the potential treatment of anxiety.

3M Pharmaceuticals, St. Paul, MN (1995 to 2000)

Research Specialist; Led project teams and medicinal chemistry efforts investigating PDE4 inhibitors for the treatment of asthma and immune response modifiers for the treatment of viral diseases.

### Representative Patents and Published Patent Applications

US 7,335,773: Intermediates for imidazonaphthyridines. Graceway Pharmaceuticals, LLC. **2008**, Gerster, J., Lindstrom, K., Crooks, S., Heppner, P., Marszalek, G., Maye, P., Merrill, B., Mickelson, J., Rice, M.

US 7,176,242: N,N'-Substituted -1,3-diamino-2-hydroxypropane derivatives. Elan Pharmaceuticals Inc. and Pharmacia and Upjohn Co. **2007**, Varghese, J., Maillard, M., Jagodzinska, B., Beck, J., Gailunas, A., Freskos, J., Mickelson, J., Samala, L., Sealy, J., Tenbrink, R., Fang, L., Hom, R.

US20060194817: N-(3-Amino-2-hydroxy-propyl) substituted alkylamide compounds. Pharmacia and Elan, **2006**, Gailunas, A., Tucker, J., Tenbrink R., Mickelson, J.

US 7,038,051: Imidazonaphthyridines. 3M Innovative Properties Co. **2006**, Gerster, J., Lindstrom, K., Crooks, S., Heppner, P., Marszalek, G., Maye, P., Merrill, B., Mickelson, J., Rice, M.

US 6,989,389: Aryl ether substituted imidazoquinolines. 3M Innovative Properties Co. **2006**, Heppner, P., Charles, L., Dellaria, J., Merrill, B., Mickelson, J.

EP1565454: Pyrazine compounds as CRF modulators. Pharmacia and Upjohn Company LLC. **2005**, Mickelson, J.

EP1409450: N-(3-Amino-2-hydroxy-propyl) Substituted Alkylamide Compounds. Elan Pharm Inc. and Upjohn Co. **2004**, Gailunas, A., Tucker, J., Tenbrink, R., Mickelson, J.